Completed PHASE2 INTERVENTIONAL 1-arm NCT01196559

Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer

A Phase II Study of Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Epithelial Ovarian/Fallopian Tube/ Primary Peritoneal Carcinoma.

Sponsor: Korean Cancer Study Group

Conditions Fallopian Tube Cancer Ovarian Cancer Primary Peritoneal Cancer

Interventions Vinorelbine and Gemcitabine

Updated 6 times since 2017 Last updated: Feb 14, 2015 Started: Jan 31, 2011 Primary completion: Oct 31, 2014 Completion: Oct 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Fallopian Tube Cancer and Ovarian Cancer and is currently completed. Korean Cancer Study Group leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Korean Cancer Study Group
The Catholic University of Korea

Data source: The Catholic University of Korea

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jinju, South Korea
• Seoul, South Korea